FDA Early Alzheimer’s Disease Comment Letter

In February 2018, the FDA issued early guidance on clinical trials for early Alzheimer’s disease. The document lays out the FDA’s thinking on how to meaningfully include patients in clinical trials at the earliest stages of the disease. The attached document is a sign-on comment letter circulated by ACT-AD in response to the draft guidance.

Read the FDA Draft Guidance Document Here